华法林对阵发性房颤患者抗凝治疗的效果分析

张锋让

（陕西省宝鸡市岐山县医院，陕西 宝鸡，722400）

浏览次数：116次 下载次数：472次

摘要：

目的 探讨在阵发性房颤患者的抗凝治疗中使用华法林的效果。方法 选取2013年2月至2015年2月我院收治的阵发性房颤患者86 例为研究对象，按照住院顺序分为试验组和对照组，每组43例。试验组患者给予华法林治疗，对照组患者给予阿司匹林治疗，对比两组患者治疗后的血栓栓塞、出血及不良反应发生情况。结果 试验组患者治疗后的血栓栓塞发生 率为4.65%，不良反应发生率为9.30%，均低于对照组患者的32.56%、37.21%，差异具有统计学意义（P<0.05）。试验组患者治 疗后出血发生率为6.98%，对照组患者治疗后出血发生率为9.30%，两组患者出血发生率比较，差异没有统计学意义（P> 0.05）。结论 华法林对阵发性房颤患者抗凝治疗效果较好，血栓栓塞及不良发应发生率较低，值得临床推广。

关键词：华法林；阿司匹林；阵发性房颤；抗凝治疗

中图分类号：R541.75文献标志码：A文章编号：2096-1413(2016)25-0097-02

The clinical effect of warfarin on anticoagulant therapy in the paroxysmal atrial fibrillation
ZHANG Feng-rang
(Qishan County Hospital of Baoji City, Baoji 722400, China)

ABSTRACT: Objective To explore the effect of warfarin on anticoagulant therapy in paroxysmal atrial fibrillation patients. Methods Eighty-six cases of paroxysmal atrial fibrillation patients were enrolled from February 2013 to February 2015, who were allocated as the order of hospitalization to receive warfarin (study group, n=43) and aspirin (control group, n=43) respectively. The status of thromboembolism, bleeding and the adverse reaction between the two groups were compared. Results The incidence of thromboembolism (4.65%) and adverse reaction (9.30%) in study group was lower than that in control group with 32.56% and 37.21% respectively, and the difference was significant (P<0.05). The bleeding incidence of the study group was 6.98%, which was not different from 9.30% of the control group (P>0.05). Conclusion The warfarin deserved popularization in clinical because of the great effect on the paroxysmal atrial fibrillation and the lower incidence of the thromboembolism and adverse reaction.
KEYWORDS: warfarin; aspirin; paroxysmal atrial fibrillation; anticoagulant therapy

参考文献：
[1] 邱明霞,覃小芬.华法林两种抗凝方案治疗阵发性房颤的临床疗效与安全性分析[J].内科,2015,10(4):466-467.
[2] 章玲,李军,麦爱欢,等.心房颤动射频消融术后利伐沙班和华法林抗凝治疗对比研究[J].中华临床医师杂志:电子版,2015,9(12):118-120.


[3] 翟永新.阵发性房颤两种抗凝方案的疗效和安全性的对比研究[J]. 心血管病防治知识(下半月),2014(9):88-89.
[4] 徐轩,王彬,陈三.华法林、阿司匹林对老年阵发性心房颤动患者抗栓治疗的疗效观察[J].中西医结合心脑血管病杂志,2015,13(1):118-119.
[5] 衣欣,吴威,蒙奕兵,等.老年人房颤与NT-ProBNP、左房大小的关系及抗凝现状分析[J].临床和实验医学杂志,2013,12(12):926-927.
[6] 鲍东来,姜昌浩,宗金波,等.慢性肾功能不全对房颤患者使用华法林的影响[J].全科医学临床与教育,2015,13(2):156-157.
[7] 伊西春.华法林与阿司匹林用于老年阵发性房颤患者抗凝治疗的临床对比研究[J].中国医药指南,2013,11(13):409-410.
[8] SAKSENA S,HETTRICK DA,KOCHLER JL,et al.Progression of paroxysmal atrial fibrillation to persistent atrial fibrillation in patients with bradyarrhythmias[J].Am Heart,2007,154(5):884-892.
[9] BOK SK,LEE YJ,AHN SY.Recurrent cerebral infarction caused by mobile aortic arch thrombus refractory to warfarin therapy.Ann Rehabil Med[J].2013,37(5):750-754.
[10] 俞集会.华法林与阿司匹林用于老年阵发性房颤患者抗凝治疗临床对比研究[J].中国实用医药,2013,8(19):66-67.
[11] CHENG H,DAI YY,JIANG RH,et al.Non-pulmonary vein foci induced before and after plumonary vein isolation in patients undergoing ablation therapy for paroxysmal atrial fibrillation: incidence and clinical outcome[J]J.Zhejiang Univ.Sci.B,2014,15(10):915-922.
[12] 张澍,孙彤,程仁立,等.基层医院非瓣膜病性心房颤动患者抗凝治疗现状及华法林最佳初始剂量研究[J].蚌埠医学院学报,2014,36(7):698-700.